Sampo launches further sale of Nordea shares
SAMPO PLC INSIDE INFORMATION 9 September 2021 at 7:10 pm
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW
Sampo launches further sale of Nordea shares
Sampo has today announced the launch of an accelerated bookbuild offering of a maximum of 73 million Nordea shares to institutional investors. The offering implies a potential reduction in Sampo’s stake in Nordea of up to 1.8 percentage points to 10.1 per cent of all outstanding shares.
The planned disposal represents a further step toward Sampo’s aim to materially reduce its ownership in Nordea by end of August 2022 in order to focus its strategy and capital allocation toward P&C insurance.
The result of the transaction will be announced on 10 September 2021 at the latest. In connection with the offering, Sampo has entered into a lock-up undertaking, under which it has, subject to certain exceptions, agreed not to sell any Nordea shares for a period ending at 8 November 2021. The book value of the Nordea holding in Sampo Group’s consolidated balance sheet was EUR 7.93 per share on 30 June 2021. BofA Securities Europe SA is acting as Bookrunner of the transaction.
For more information, please contact:
Head of Investor Relations
tel. +358 10 516 0030
Communications Manager, Media Relations
tel. +358 10 516 0031
THIS ANNOUNCEMENT HAS BEEN MADE FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO BUY, SELL, ISSUE OR SUBSCRIBE FOR, OR THE SOLICITATION OF AN OFFER TO BUY, SELL, ISSUE OR SUBSCRIBE FOR ANY SECURITIES, NOR SHALL THERE BE ANY SALE OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
IN THE UNITED KINGDOM, THIS ANNOUNCEMENT IS ONLY BEING DISTRIBUTED TO AND IS DIRECTED AT “QUALIFIED INVESTORS” WITHIN THE MEANING OF ARTICLE 2(E) OF REGULATION (EU) 2017/1129, AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, (A) HAVING PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”); (B) WHO ARE HIGH NET WORTH ENTITIES DESCRIBED IN ARTICLE 49(2) (A) TO (D) OF THE ORDER; OR (C) OTHER PERSONS TO WHOM THEY MAY LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS “RELEVANT PERSONS”). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES WILL ONLY BE AVAILABLE TO AND WILL ONLY BE ENGAGED IN WITH RELEVANT PERSONS. ANY PERSON WHO IS NOT A RELEVANT PERSON SHOULD NOT ACT OR RELY ON THIS ANNOUNCEMENT OR ANY OF ITS CONTENTS.
THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION. NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.
ANY INVESTMENT DECISION TO BUY SECURITIES IN THE EQUITY OFFERING MUST BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION WHICH HAS NOT BEEN INDEPENDENTLY VERIFIED BY THE SOLE BOOKRUNNER OR THE SELLER. NEITHER THIS ANNOUNCEMENT NOR ANY COPY OF IT MAY BE TAKEN, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES, AUSTRALIAN, CANADIAN, JAPANESE OR OTHER APPLICABLE SECURITIES LAWS.
THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFERING OR SALE OF THE SECURITIES REFERRED TO HEREIN IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. NO ACTION HAS BEEN TAKEN BY THE SOLE BOOKRUNNER OR ANY OF ITS RESPECTIVE AFFILIATES OR ANY OTHER PERSON THAT WOULD PERMIT AN OFFER OF THE SECURITIES REFERRED TO HEREIN OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT OR ANY OTHER OFFERING OR PUBLICITY MATERIAL RELATING TO THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED BY THE SOLE BOOKRUNNER TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS.
THE SOLE BOOKRUNNER IS ACTING EXCLUSIVELY FOR THE SELLER AND NO ONE ELSE IN CONNECTION WITH THE EQUITY OFFERING. THE SOLE BOOKRUNNER WILL NOT REGARD ANY OTHER PERSON (WHETHER OR NOT A RECIPIENT OF THIS ANNOUNCEMENT) AS ITS CLIENT IN RELATION TO THE EQUITY OFFERING AND THE SOLE BOOKRUNNER WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN THE SELLER FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR CLIENTS NOR FOR GIVING ADVICE IN RELATION TO THE OFFERING OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. THE SOLE BOOKRUNNER MAY PARTICIPATE IN THE OFFERING ON A PROPRIETARY BASIS.
London Stock Exchange
The principal media
Financial Supervisory Authority
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid
Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release
September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0
21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release
Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto
Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release
Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665
Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release
PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020
Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release
CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic